Aberrant IgA1 Glycosylation in IgA Nephropathy: A Systematic Review.
Galactose-deficient IgA1 was evaluated in patients with IgA nephropathy(IgAN) and controls in order to determine the predictive value of galactose-deficient IgA1 in cases of IgA nephropathy.PubMed, EMBASE, Cochrane central register of controlled trials, CNKI, CBM disc, and VIP database were searched...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2016-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC5117702?pdf=render |
| _version_ | 1818288390166020096 |
|---|---|
| author | Qiang Sun Zhenhai Zhang Hong Zhang Xiaorong Liu |
| author_facet | Qiang Sun Zhenhai Zhang Hong Zhang Xiaorong Liu |
| author_sort | Qiang Sun |
| collection | DOAJ |
| description | Galactose-deficient IgA1 was evaluated in patients with IgA nephropathy(IgAN) and controls in order to determine the predictive value of galactose-deficient IgA1 in cases of IgA nephropathy.PubMed, EMBASE, Cochrane central register of controlled trials, CNKI, CBM disc, and VIP database were searched to identify eligible studies that evaluated a difference in aberrant IgA1 glycosylation in IgAN patients compared with controls. A meta-analysis was conducted to evaluate the impact of galactose-deficient IgA1(Gd-IgA1) levels in different groups.A total of 22 studies (n = 1657) met inclusion criteria. The mean Newcastle-Ottawa Scale (NOS) score was 7.2 and ranged from 6 to 8. The standard mean difference(SMD) in the meta-analysis of 20 studies of the level of Gd-IgA1 in the serum and/or supernatant of cultured cells was higher in the IgAN group compared with healthy controls as well as in those with other renal diseases (SMD = 1.76, 95% CI = 1.18-2.34, P<0.00001; SMD = 1.05, 95% CI = 0.05-2.04, P = 0.04). The data synthesis suggested that IgAN patients had similar levels of serum Gd-IgA1, with no significant differences, compared with first-degree relatives and Henoch-Schonlein purpura nephritis (HSPN) patients (MD = 0.04, 95% CI = 0.00-0.08, P = 0.05; MD = -46.03, 95% CI = -217.70-125.64, P = 0.60). In addition, the combined MD of 5 studies indicated that there were no significant differences in Gd-IgA1 levels among patients with varying severities of IgAN (MD = 0.02, 95% CI = -0.02-0.05, P = 0.28).The pooled evidence suggests that the level of Gd-IgA1 in the serum or supernatant of cultured cells from peripheral blood or tonsils may be a useful biomarker for predicting IgA nephropathy, though the level of Gd-IgA1 was not significantly associated with disease severity. |
| first_indexed | 2024-12-13T01:55:37Z |
| format | Article |
| id | doaj.art-8cd0597bb69e40749631ac2de5fdd5be |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-13T01:55:37Z |
| publishDate | 2016-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-8cd0597bb69e40749631ac2de5fdd5be2022-12-22T00:03:24ZengPublic Library of Science (PLoS)PLoS ONE1932-62032016-01-011111e016670010.1371/journal.pone.0166700Aberrant IgA1 Glycosylation in IgA Nephropathy: A Systematic Review.Qiang SunZhenhai ZhangHong ZhangXiaorong LiuGalactose-deficient IgA1 was evaluated in patients with IgA nephropathy(IgAN) and controls in order to determine the predictive value of galactose-deficient IgA1 in cases of IgA nephropathy.PubMed, EMBASE, Cochrane central register of controlled trials, CNKI, CBM disc, and VIP database were searched to identify eligible studies that evaluated a difference in aberrant IgA1 glycosylation in IgAN patients compared with controls. A meta-analysis was conducted to evaluate the impact of galactose-deficient IgA1(Gd-IgA1) levels in different groups.A total of 22 studies (n = 1657) met inclusion criteria. The mean Newcastle-Ottawa Scale (NOS) score was 7.2 and ranged from 6 to 8. The standard mean difference(SMD) in the meta-analysis of 20 studies of the level of Gd-IgA1 in the serum and/or supernatant of cultured cells was higher in the IgAN group compared with healthy controls as well as in those with other renal diseases (SMD = 1.76, 95% CI = 1.18-2.34, P<0.00001; SMD = 1.05, 95% CI = 0.05-2.04, P = 0.04). The data synthesis suggested that IgAN patients had similar levels of serum Gd-IgA1, with no significant differences, compared with first-degree relatives and Henoch-Schonlein purpura nephritis (HSPN) patients (MD = 0.04, 95% CI = 0.00-0.08, P = 0.05; MD = -46.03, 95% CI = -217.70-125.64, P = 0.60). In addition, the combined MD of 5 studies indicated that there were no significant differences in Gd-IgA1 levels among patients with varying severities of IgAN (MD = 0.02, 95% CI = -0.02-0.05, P = 0.28).The pooled evidence suggests that the level of Gd-IgA1 in the serum or supernatant of cultured cells from peripheral blood or tonsils may be a useful biomarker for predicting IgA nephropathy, though the level of Gd-IgA1 was not significantly associated with disease severity.http://europepmc.org/articles/PMC5117702?pdf=render |
| spellingShingle | Qiang Sun Zhenhai Zhang Hong Zhang Xiaorong Liu Aberrant IgA1 Glycosylation in IgA Nephropathy: A Systematic Review. PLoS ONE |
| title | Aberrant IgA1 Glycosylation in IgA Nephropathy: A Systematic Review. |
| title_full | Aberrant IgA1 Glycosylation in IgA Nephropathy: A Systematic Review. |
| title_fullStr | Aberrant IgA1 Glycosylation in IgA Nephropathy: A Systematic Review. |
| title_full_unstemmed | Aberrant IgA1 Glycosylation in IgA Nephropathy: A Systematic Review. |
| title_short | Aberrant IgA1 Glycosylation in IgA Nephropathy: A Systematic Review. |
| title_sort | aberrant iga1 glycosylation in iga nephropathy a systematic review |
| url | http://europepmc.org/articles/PMC5117702?pdf=render |
| work_keys_str_mv | AT qiangsun aberrantiga1glycosylationiniganephropathyasystematicreview AT zhenhaizhang aberrantiga1glycosylationiniganephropathyasystematicreview AT hongzhang aberrantiga1glycosylationiniganephropathyasystematicreview AT xiaorongliu aberrantiga1glycosylationiniganephropathyasystematicreview |